Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors

被引:0
|
作者
Yared, Jean A. [1 ]
Lee, Tsung-Ying [2 ]
Cooke, Catherine E. [2 ]
Johnson, Abree [2 ]
Summers, Amanda [2 ]
Yang, Keri [3 ]
Liu, Sizhu [3 ]
Tang, Boxiong [3 ]
Onukwugha, Eberechukwu [2 ]
机构
[1] Univ Maryland, Sch Med, Dept Med, Baltimore, MD USA
[2] Univ Maryland, Sch Pharm, Dept Practice Sci & Hlth Outcomes Res, 220 Arch St, Baltimore, MD 21201 USA
[3] Beigene USA Inc, San Mateo, CA USA
关键词
Treatment patterns; social determinants of health; social vulnerability index; chronic lymphocytic leukemia; INITIAL THERAPY; IBRUTINIB; CANCER; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; VENETOCLAX; RITUXIMAB;
D O I
10.1080/10428194.2024.2310150
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study characterizes the patterns and timing of CLL treatment and, to our knowledge, is the first to identify social vulnerability factors associated with CLL treatment receipt in the Medicare population. A total of 3508 Medicare beneficiaries diagnosed with CLL from 2017 to 2019 were identified. We reported the proportion of individuals who received CLL treatment and the time until the first CLL treatment receipt after the first observed claim with a CLL diagnosis. Logistic regression and time-to-event models provided adjusted odds ratios and hazard ratios associated with baseline individual-level and county-level factors. Sixteen percent of individuals received CLL treatment, and the median follow-up time was 540 d. The median time to receipt of CLL treatment was 61 d. Older age and residence in a county ranked high in social vulnerability (as defined by minority status and language) were negatively associated with treatment receipt and time to treatment receipt.
引用
收藏
页码:598 / 608
页数:11
相关论文
共 50 条
  • [21] Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era
    Mato, Anthony
    Jahnke, Jordan
    Li, Pengxiang
    Mehra, Maneesha
    Ladage, Vrushabh P.
    Mahler, Michelle
    Huntington, Scott
    Doshi, Jalpa A.
    HAEMATOLOGICA, 2018, 103 (10) : E462 - E465
  • [22] Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    Agathangelidis, Andreas
    Sutton, Lesley Ann
    Hadzidimitriou, Anastasia
    Tresoldi, Cristina
    Langerak, Anton W.
    Belessi, Chrysoula
    Davi, Frederic
    Rosenquist, Richard
    Stamatopoulos, Kostas
    Ghia, Paolo
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2018, (141):
  • [23] Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection
    Bantilan, Kurt S.
    Kay, Neil E.
    Parikh, Sameer A.
    Rabe, Kari G.
    Call, Timothy G.
    Leis, Jose F.
    Ding, Wei
    Slager, Susan L.
    Soumerai, Jacob D.
    Roeker, Lindsey E.
    Mato, Anthony
    Zelenetz, Andrew D.
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 300 - 311
  • [24] Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center
    Ranti, Juha
    Perkonoja, Katariina
    Kauko, Tommi
    Loponen, Heidi
    Joensuu, Emmi I.
    Jarvinen, Tiina M.
    EJHAEM, 2022, 3 (01): : 291 - 300
  • [25] EXPERIENCE OF IBRUTINIB THERAPY IN THE TREATMENT OF PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Kurkina, N. V.
    Repina, E. A.
    Mashnina, N. N.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (01): : 55 - 56
  • [26] Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies
    Mato, Anthony R.
    Samp, Jennifer C.
    Gauthier, Genevieve
    Terasawa, Emi
    Brander, Danielle M.
    CANCER BIOLOGY & THERAPY, 2018, 19 (07) : 636 - 643
  • [27] New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia
    Elżbieta Iskierka-Jażdżewska
    Agnieszka Obracaj
    Marta Urbaniak
    Tadeusz Robak
    Current Treatment Options in Oncology, 2022, 23 : 775 - 795
  • [28] Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020
    Huntington, Scott F.
    Ingham, Michael P.
    Okonkwo, Linda
    Singh, Ajaybir
    Wang, Ruibin
    Ammann, Eric M.
    LEUKEMIA & LYMPHOMA, 2022, 63 (05) : 1180 - 1190
  • [29] Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada
    Huang, Steven J.
    Gerrie, Alina S.
    Young, Sean
    Tucker, Tracy
    Bruyere, Helene
    Hrynchak, Monica
    Galbraith, Paul
    Al Tourah, Abdulwahab J.
    Dueck, Gregory
    Noble, Michael C.
    Ramadan, Khaled M.
    Tsang, Peter
    Hardy, Edward
    Sehn, Laurie
    Toze, Cynthia L.
    LEUKEMIA RESEARCH, 2020, 91
  • [30] Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia
    Nabhan, Chadi
    Chaffee, Kari G.
    Slager, Susan L.
    Galanina, Natalie
    Achenbach, Sara J.
    Schwager, Susan M.
    Kay, Neil E.
    Shanafelt, Tait D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (07) : 677 - 680